FossellaF.V., De VoreF., KerrR.N.: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum containing chemotherapy regimens.J Clin Oncol18: 2354–2362, 2000.
2.
ShepherdF.A., DanceyJ., RamlauR.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum based chemotherapy.J Clin Oncol18: 2095–2103, 2000.
3.
SerkeM., LambiriI., SboenfeldN.: Weekly docetaxel as second line therapy of advanced non-small cell lung cancer (NSCLC): a preliminary feasibility report.Proc ASCO19: 2146 (abst), 2000.
4.
LilenbaumR., SchwartzM., SeigelL.: Phase II trial of weekly docetaxel (I) in second-line non-small cell lung cancer (NSCLC).Proc ASCO19: 2034 (abst), 2000.
5.
HainsworthJ.D., BurrisH.A., ErlandJ.B.: Phase I trial of docetaxel administred by weekly infusion in patients with advanced refractory cancer.J Clin Oncol16: 2164–2168, 1998.
6.
RodriguezJ., PawelJ., PluzanskaA.: A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer.Proc ASCO20: 1252 (abst), 2001.
7.
NeubauerM., GarfieldD., KhanM.: Phase-II trial of weekly docetaxel plus gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC).Proc ASCO20: 2760 (abst), 2001.
8.
GeorouliasV.: Platinum based and non-platinum based chemotherapy in advanced non small cell lung cancer: a randomized multicentre trial.Lancet357: 1478–1484, 2001.
9.
KourousisC., AndroulakisN., KakolirysS.: First-line treatment of advanced non-small cell lung carcinoma with docetaxel and vinorelbine.Cancer83: 2083–2090, 1998.
10.
Trillet-LenoirV., MonnierA., DouillardJ.Y.: Interim results of a phase II study of docetaxel and vinorelbine in chemotherapy naïve patients with advanced non-small cell lung cancer.Ann Oncol7: 95, 1996 (Suppl: 5) abstract 450P.
11.
KrugM.E., MillerV.A.: Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.Sem Oncol26(suppl 16): 24–26, 1999.
12.
WallsJ.A., O'RourkeM., GarfieldD.: First-line therapy of taxotere (T) and navelbine (N) in patients with advanced non-small cell lung cancer (NSCLC). A phase II study.Proc ASCO19: 2158, 2000.
13.
GandaraD.R., LovatoL.C., AlbainK.S.: Phatological stage IIIb non-small cell lung cancer. Prolonged survival with consolidation of docetaxel following concurrent chemoradiotherapy (SWOG 9504).Lung Cancer29: 92, 2000 (Suppl. 1) abstract 302.
14.
ManegoldC., PilzL., KoschelG.: Single agent gemcitabine and docetaxel given sequentially in various doses and schedules are effective in advanced NSCLC: survival data from two (I, II) randomised phase II studies.Proc ASCO20: 1346 (abst), 2001.
15.
Fossella: Docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCb) vs vinolrelbine + cisplatin (VC) in chemotherapy naive patients with advanced and metastatic NSCLC: results of a multicenter randomized phase III study.Eur J Cancer, 137(suppl 6): 562(abst), 2001.
